Mereo Biopharma Group Stock Current Ratio
0A9G Stock | 3.54 0.14 4.12% |
Mereo BioPharma Group fundamentals help investors to digest information that contributes to Mereo BioPharma's financial success or failures. It also enables traders to predict the movement of Mereo Stock. The fundamental analysis module provides a way to measure Mereo BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mereo BioPharma stock.
Mereo | Current Ratio |
Mereo BioPharma Group Company Current Ratio Analysis
Mereo BioPharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition |
In accordance with the recently published financial statements, Mereo BioPharma Group has a Current Ratio of 0.0 times. This is 100.0% lower than that of the Commercial Services & Supplies sector and about the same as Industrials (which currently averages 0.0) industry. The current ratio for all United Kingdom stocks is 100.0% higher than that of the company.
Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
All Next | Launch Module |
Mereo Fundamentals
Return On Equity | -0.74 | |||
Return On Asset | -0.31 | |||
Operating Margin | (38.07) % | |||
Current Valuation | 2.53 B | |||
Shares Owned By Insiders | 1.02 % | |||
Shares Owned By Institutions | 68.29 % | |||
Revenue | 1000 K | |||
Gross Profit | 936 K | |||
EBITDA | (37.48 M) | |||
Net Income | (34.2 M) | |||
Book Value Per Share | 0.47 X | |||
Cash Flow From Operations | (38.82 M) | |||
Earnings Per Share | (0.28) X | |||
Target Price | 4.38 | |||
Number Of Employees | 33 | |||
Beta | 0.97 | |||
Retained Earnings | (331.16 M) |
About Mereo BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mereo BioPharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mereo BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mereo BioPharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.